Rockwell Medical (RMTI) investor relations material

Executive summary

• Q3 net sales rose 20% YoY to $19.1M and gross profit increased 37% to $3.1M; net loss widened to $2.3M, including $0.8M in acquisition-related costs.

• Nine-month sales increased 7% to $54.2M and gross profit rose 18% to $9.3M; operating cash flow was positive $0.4M versus $3.0M used in 2025.

• 2026 guidance was withdrawn following the proposed Vantive acquisition, which is projected to support $400M–$450M in combined annual revenue.

Financial highlights

• Q3 net sales were $19.1M versus $15.9M YoY; gross profit was $3.1M versus $2.3M, and operating loss was $2.2M versus $1.6M.

• Q3 net loss was $2.3M versus $1.8M; basic and diluted loss per share was $0.59 versus $0.49.

• Nine-month sales were $54.2M versus $50.9M; gross profit was $9.3M versus $7.8M, and operating loss was $4.8M versus $4.3M.

• Nine-month net loss was $5.1M versus $4.8M; loss per share was $1.33 versus $1.41.

• Q3 and nine-month 2026 results each included $0.8M in acquisition-related legal, consulting and professional fees; comparable 2025 periods had none.

Outlook and guidance

• 2026 guidance for sales, gross margin, Adjusted EBITDA and operating cash flow was withdrawn due to expected acquisition-related transaction and financing expenses.

• Combined annual revenue is projected at $400M–$450M, with ~90% recurring based on current revenue profiles; closing is expected in mid-2027, subject to conditions and approvals.

• Full-company guidance is expected after the Form 10-K, with an estimate anticipated in March.

• Sufficient funds for operating requirements were expected for at least 12 months from filing, excluding acquisition impacts.